Necrosis in Medical Technology
Navigation Links
Necrosis in Medical Technology
... pegol) - the only PEGylated anti-TNF (Tumor necrosis Factor)
- presented at the American College of ... more recent addition. Anti-TNF
(TNF-alpha; Tumor necrosis Factor) therapies are specific types ... CIMZIA is the only PEGylated anti-TNF (Tumor necrosis Factor). CIMZIA
has a high affinity for human ...
... Employer Claims Suggests a Benefit of Anti-Tumor necrosis Factor Therapies on Absenteeism Among Employees ... and Drug Administration as the first anti-tumor necrosis factor (TNF)-alpha therapy, REMICADE received its ... is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is first ...
... first and only PEGylated Fc-free anti-TNF (Tumor necrosis Factor), given with methotrexate, is ... of treatment options. Anti-TNF (TNF-alpha; Tumor necrosis Factor) therapies are specific types of ... the first and only PEGylated anti-TNF (Tumor necrosis Factor). CIMZIA is Fc- free and thus avoids ...
... also inhibited the effect of inflammatory cytokines, including tumor necrosis factor (TNF-alpha) and interleukin (IL-4) on intestinal epithelial ... from a study investigating the effect of larazotide acetate on tumor necrosis factor (TNF-alpha) and interleukin (IL-4) induced permeability. The study ...
... CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor necrosis Factor alpha) - provides sustained improvement in symptoms with stable ... (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment ...
... clinical trial, the first of its kind to compare REMICADE, an anti-tumor necrosis factor (TNF)-alpha therapy, with an immunomodulator in patients with ... About REMICADE REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is first anti-TNF-alpha treatment ...
... may itch and bleed. This chronic inflammation is driven in part by tumor necrosis factor alpha, or TNF-alpha, a cytokine involved in the body's normal ... About REMICADE REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is the only anti-TNF-alpha ...
... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ...
... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ...
... therapy." Upon receipt of the corresponding Commission Decision, SIMPONI will be the first and only once-monthly subcutaneous anti-tumor necrosis factor (TNF) alpha therapy approved in Europe for the simultaneous treatment of RA, PsA, and AS. SIMPONI will be available in two device forms, ...
... that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements ...
... maintaining steroid-free remission through one year." The SONIC clinical trial is the first of its kind to compare REMICADE, an anti-tumor necrosis factor (TNF)-alpha therapy, with an immunomodulator (azathioprine) in patients with moderate to severe Crohn's disease. Azathioprine is not approved ...
... bowel diseases and many patients do not respond to or cannot tolerate current treatment options, including the newer biologics such as anti-Tumor necrosis Factor (TNF) agents, which need to be injected or infused. There was no evidence of an increased risk of infection with Traficet-EN in PROTECT-1. ...
... it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. About The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies The Sixth International ...
... toward mitogen (phytohemagglutinin [PHA]) and cytokine production of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, and (alpha)-tumor necrosis factor. Results demonstrated that the AHCC group (n=10) after intake had a significantly higher number of total DCs compared to baseline and ...
... Cause of shortened lifespan The negative effect upon lifespan with mega-dose resveratrol may emanate from over-inhibition of tumor necrosis factor (TNF), an inflammatory factor. Excessive TNF leads to inflammation, while too little impairs the immune system, says Sardi. "We know ...
... hydroxyurea period). No significant difference was observed between the two treatments for the prevention or reduction of the frequency of avascular necrosis (blockage of small vessels in the bone area causing destruction to joints) or cerebrovascular episodes (blockage of small blood vessels in the ....
... to be numerically lower that those when the patients were on placebo injections." About Enbrel Enbrel is a fully human soluble tumour necrosis factor (TNF) receptor. Enbrel was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 ...
... San Francisco, October 24-29. Results of the RADIATE study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies, demonstrated that half of patients treated with ACTEMRA (8 mg/kg) in combination with methotrexate achieved a 20 ...
... colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment option for people with RA. CIMZIA has a high affinity for human TNF-alpha, ...
... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
... 50 years or older and were provided AHCC for 60 days. Scientists measured the production of two key cytokines -- Interferon (IFN-y) and Tumor necrosis Factor (TNF-alpha) -- at the baseline, 30 days and 60 days. These two cytokines are believed to serve a major role in the body's natural method ...
... today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients ...
... Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis. In the study, ...
... specimens revealed definitive expression of the GM-CSF transgene in cancer cells indicating effective gene delivery in vivo. Further, extensive tumor necrosis and tumor infiltrating lymphocytes (TILs) were observed within the tumors. Characterization of the recruited TILs showed CD35+ dendritic cells, ...
... monitored and have regular follow-up visits with a physician. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune ...
... (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX). ORENCIA should not be administered concomitantly with tumor necrosis factor (TNF) antagonists and is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This ...
... patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate ...
... standard antiplatelet treatment (75 mg clopidogrel and 325 mg aspirin daily). Patients had serial assessment of platelet reactivity, myocardial necrosis markers, and inflammatory markers at baseline, 2 hours, 8 hours, and 18-24 hours post-stenting. Blood work was processed at The Sinai Center for ...
... -- 1 patient (11 prior regimens, 5 with trastuzumab, 2 with lapatinib) showed 10% reduction in tumor mass with change consistent with tumor necrosis and a decrease in 2 tumor markers (64% CEA, 63% CA27.29); -- 1 patient (5 prior regimens) showed a partial response after 2 cycles, confirmed ...
... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
... Employer Claims Suggests a Benefit of Anti-Tumor necrosis Factor Therapies on Absenteeism Among Employees ... and Drug Administration as the first anti-tumor necrosis factor (TNF)-alpha therapy, REMICADE received its ... is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is first ...
... first and only PEGylated Fc-free anti-TNF (Tumor necrosis Factor), given with methotrexate, is ... of treatment options. Anti-TNF (TNF-alpha; Tumor necrosis Factor) therapies are specific types of ... the first and only PEGylated anti-TNF (Tumor necrosis Factor). CIMZIA is Fc- free and thus avoids ...
... also inhibited the effect of inflammatory cytokines, including tumor necrosis factor (TNF-alpha) and interleukin (IL-4) on intestinal epithelial ... from a study investigating the effect of larazotide acetate on tumor necrosis factor (TNF-alpha) and interleukin (IL-4) induced permeability. The study ...
... CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor necrosis Factor alpha) - provides sustained improvement in symptoms with stable ... (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment ...
... clinical trial, the first of its kind to compare REMICADE, an anti-tumor necrosis factor (TNF)-alpha therapy, with an immunomodulator in patients with ... About REMICADE REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is first anti-TNF-alpha treatment ...
... may itch and bleed. This chronic inflammation is driven in part by tumor necrosis factor alpha, or TNF-alpha, a cytokine involved in the body's normal ... About REMICADE REMICADE is the global market leader among anti-tumor necrosis factor alpha (TNF-alpha) therapies and is the only anti-TNF-alpha ...
... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ...
... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ... Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most ...
... therapy." Upon receipt of the corresponding Commission Decision, SIMPONI will be the first and only once-monthly subcutaneous anti-tumor necrosis factor (TNF) alpha therapy approved in Europe for the simultaneous treatment of RA, PsA, and AS. SIMPONI will be available in two device forms, ...
... that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements ...
... maintaining steroid-free remission through one year." The SONIC clinical trial is the first of its kind to compare REMICADE, an anti-tumor necrosis factor (TNF)-alpha therapy, with an immunomodulator (azathioprine) in patients with moderate to severe Crohn's disease. Azathioprine is not approved ...
... bowel diseases and many patients do not respond to or cannot tolerate current treatment options, including the newer biologics such as anti-Tumor necrosis Factor (TNF) agents, which need to be injected or infused. There was no evidence of an increased risk of infection with Traficet-EN in PROTECT-1. ...
TNFerade(TM) Phase III Data Presented at ASCO
... About TNFerade(TM) TNFerade, which has not yet been approved for use, is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNF alpha), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After ...Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... low level of discontinuations due to adverse events (5%). About CIMZIA (R) CIMZIA (R) is the only PEGylated anti-TNF (Tumour necrosis Factor). Cimzia (R) has a high affinity for human TNF-alpha, selectively neutralising the pathophysiological effects of TNF-alpha. Over the past ...... it is selectively toxic to cancer calls via a process called chemoablation whereby cells undergo a form of cell death that mimics both features of necrosis and apoptosis. About The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies The Sixth International ...
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
... the treatment of eosinophilic asthma in adults. Ception also has an established program to discover small molecule, orally-active, anti-TNF (tumor necrosis factor) receptor agents. Cephalon may exercise its option at any time prior to expiration of a specified period after receipt of the final ...... toward mitogen (phytohemagglutinin [PHA]) and cytokine production of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon gamma-gamma, and (alpha)-tumor necrosis factor. Results demonstrated that the AHCC group (n=10) after intake had a significantly higher number of total DCs compared to baseline and ...
... Cause of shortened lifespan The negative effect upon lifespan with mega-dose resveratrol may emanate from over-inhibition of tumor necrosis factor (TNF), an inflammatory factor. Excessive TNF leads to inflammation, while too little impairs the immune system, says Sardi. "We know ...
... hydroxyurea period). No significant difference was observed between the two treatments for the prevention or reduction of the frequency of avascular necrosis (blockage of small vessels in the bone area causing destruction to joints) or cerebrovascular episodes (blockage of small blood vessels in the ....
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
... of moderately severe to severe, active rheumatoid arthritis in adult patients who did not respond adequately to treatment with DMARDs or tumor necrosis factor (TNF) inhibitors. RoActemra can be administered as a monotherapy or in combination with methotrexate and/or other conventional DMARDs. There ...... to be numerically lower that those when the patients were on placebo injections." About Enbrel Enbrel is a fully human soluble tumour necrosis factor (TNF) receptor. Enbrel was first approved in 1998 for moderate to severe rheumatoid arthritis and has since been used in nearly 500,000 ...
... San Francisco, October 24-29. Results of the RADIATE study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies, demonstrated that half of patients treated with ACTEMRA (8 mg/kg) in combination with methotrexate achieved a 20 ...
... colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour necrosis Factor). CIMZIA is an effective, rapid-acting and long lasting treatment option for people with RA. CIMZIA has a high affinity for human TNF-alpha, ...
... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
... 50 years or older and were provided AHCC for 60 days. Scientists measured the production of two key cytokines -- Interferon (IFN-y) and Tumor necrosis Factor (TNF-alpha) -- at the baseline, 30 days and 60 days. These two cytokines are believed to serve a major role in the body's natural method ...
New Genes Found for Inflammatory Bowel Disease in Children
... gene on chromosome 20 is a compelling candidate, because it is already known to participate in the biological pathway of a protein called tumor necrosis factor (TNF). TNF is a cytokine, a chemical messenger that plays a key role in the harmful inflammation characteristic of IBD. Some current ...Pediatric Researchers Find Possible 'Master Switch' Gene in Juvenile Arthritis
... The genetic variant is on chromosome 9 in a region housing two genes, TRAF1 and C5. The TRAF1 gene codes for a protein that regulates tumor necrosis factor, a chemical strongly associated with JIA. However, the researchers say further study is needed to determine whether the TRAF1 gene or the C5 ...... today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients ...
... Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis. In the study, ...
... specimens revealed definitive expression of the GM-CSF transgene in cancer cells indicating effective gene delivery in vivo. Further, extensive tumor necrosis and tumor infiltrating lymphocytes (TILs) were observed within the tumors. Characterization of the recruited TILs showed CD35+ dendritic cells, ...
... monitored and have regular follow-up visits with a physician. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune ...
... (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX). ORENCIA should not be administered concomitantly with tumor necrosis factor (TNF) antagonists and is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This ...
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
... as achieving disease activity score (DAS) remission -- compared to DMARD therapies alone. Furthermore, patients who had previously failed anti-tumor necrosis factor (anti-TNF) treatments also showed significant improvement in signs and symptoms of RA after treatment with ACTEMRA. Roche will file a ...... patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) or tumor necrosis factor (TNF) antagonists. These data are from post-hoc analyses of two Phase III pivotal trials investigating ORENCIA: AIM (Abatacept in Inadequate ...
... standard antiplatelet treatment (75 mg clopidogrel and 325 mg aspirin daily). Patients had serial assessment of platelet reactivity, myocardial necrosis markers, and inflammatory markers at baseline, 2 hours, 8 hours, and 18-24 hours post-stenting. Blood work was processed at The Sinai Center for ...
... -- 1 patient (11 prior regimens, 5 with trastuzumab, 2 with lapatinib) showed 10% reduction in tumor mass with change consistent with tumor necrosis and a decrease in 2 tumor markers (64% CEA, 63% CA27.29); -- 1 patient (5 prior regimens) showed a partial response after 2 cycles, confirmed ...
Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
... that the first patient has been administered Cotara(R) in a new clinical trial designed to evaluate the safety and efficacy of this novel tumor necrosis therapy being developed for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer. "We are delighted that patient treatment ...... during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female ...
Other ContentsbronchiectasisbronchitisbronchitisbronchitisbronchoscopybronchoscopybronchiolitisbronchiolitisbrucellosisbruisesbruisesbubonicbubonicbubonicOther TagsBrothBrothBrothFltOther Tagscardiologist 2cardiologist 3cardiologist 4cardiologist 5cardiologist 6actually 2actually 3actually 4actually 5actually 6actually 7actually 8actually 9actually 10pull 2pull 3
(Date:12/2/2009)...HILADELPHIA Assurance of a cancer-free status did...mputerized tomography (CT) lung-cancer screening p...ers wrote in a study published in Cancer Epidemio...merican Association for Cancer Research. The Decem... These findings should negate widespread concern i...
(Date:12/2/2009)...OBOKEN - A team comprised of undergraduate student... top honors in a national poster contest hosted by...neering (ISPE). , The annual contest highlights ...d last month at the ISPE Annual Meeting in San Die...ion of a Posterior Criciate Ligament Tensioning De...
(Date:12/2/2009)...he Manpei Suzuki Diabetes Foundation is pleased to...ze: Donald F. Steiner, MD, A. N. Pritzker Distingu...edicine and Biochemistry and Molecular Biology, Th...naugurated in 2008 to commemorate the 15th anniver...oring those who have enlightened researchers in th...
Breaking Biology News(10 mins):Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2LA BioMed to honor Emil D Kakkis M D Ph D and LA County Supervisor Don Knabe 58426 1LA BioMed to honor Emil D Kakkis M D Ph D and LA County Supervisor Don Knabe 58426 2A pet in your life keeps the doctor away 10143 1A pet in your life keeps the doctor away 10143 2A pet in your life keeps the doctor away 10143 3Docs Miss Test Results Even With Alerts 58422 1Docs Miss Test Results Even With Alerts 58422 2(Date:12/2/2009)..., , WASHINGTON, Dec. 2 /PRNewswire-USNewswi...ector and CEO, Natural Products Association ,,...the U.S. Anti-Doping Agency (USADA) to educate con...s selling steroids as dietary supplements, the Nat...trade association representing retailers and manuf...
(Date:12/2/2009)...The longer the drug used, the greater the sleep di...ec. 2 (HealthDay News) -- The widely used club dru...nea, say U.S. researchers. , "People who use ec...n and can cause immediate and dangerous problems s...of the Johns Hopkins School of Medicine in Baltimo...
(Date:12/2/2009)..., , VIRGINIA BEACH, Va., Dec. 2 /PRNewswi...arette. These smokeless cigarettes continue to gro...rket is now available at the PremiumEcigarette - t...tronic cigarette - at the amazingly low price of $...or people to try the e-cigarette at a very low pri...
(Date:12/2/2009)..., ,, NEW YORK, Dec. 2 /PRNewsw...tient palliative care coordination, Advanced Illn...duce hospitalizations in the last years of life as...nd their family caregivers without increasing mort...tudy published in American Journal of Managed Car...
(Date:12/2/2009)... Waltham, MAJoseph Balboni loves sports. An avid ... the 46-year-old insurance agent became increasing... to keratoconus, a degenerative eye disorder. Unab...ed Sox games, he faced the prospect of a corneal t..., Then three years ago, Balboni discovered an alt...
Breaking Medicine News(10 mins):Health News:Natural Products Association Issues Statement on New Supplement Safety Campaign 2Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4Health News:Brandeis studies evaluate visionary approach to improving eyesight 2[0] Natural Products Association Issues Statement on New Supplement Safety Campaign[0] Ecstasy Users at Higher Risk of Sleep Apnea[2] A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product[0] Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care[1] Brandeis studies evaluate visionary approach to improving eyesight
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |